ORYZON announces First Patients in the UK in ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001
MADRID, SPAIN and CAMBRIDGE MA.
Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today that it has enrolled the first patients in the UK, at St Pancras Clinical Research, in its Phase IIa clinical study with ORY-2001 in patients of Alzheimer’s disease (AD). The study, named ETHERAL (Epigenetic THERapy in ALzheimer’s Disease), is being conducted in different European hospitals, and is designed as a randomised, double-blind, placebo-controlled, 3-arm, 26 weeks parallel-group study to evaluate the safety and tolerability of ORY2001 in patients with mild and moderate Alzheimer’s disease. The study incorporates as secondary endpoints measurements in the different dimensions of the disease, including memory and behavior alterations.. The study will also monitor the variations of diverse CSF biomarkers. This study will enroll 90 patients, and the FPIs in Spain were enrolled in May. The company is looking to launch a twin study in the US soon with a, yet to be determined, number of additional patients.